Lexicon Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1995-01-01
- Employees
- 285
- Market Cap
- $621.7M
- Website
- http://www.lexpharma.com
- Introduction
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT01818232
- Locations
- 🇺🇸
Lexicon Investigational Site, Madison, Wisconsin, United States
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT01742208
- Locations
- 🇺🇸
Lexicon Investigational Site, Dallas, Texas, United States
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
- Conditions
- Carcinoid Syndrome
- Interventions
- First Posted Date
- 2012-09-03
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 135
- Registration Number
- NCT01677910
- Locations
- 🇬🇧
Lexicon Investigational Site, Newcastle upon Tyne, United Kingdom
🇮🇱Lexicon Invetigational Site, Jerusalem, Israel
Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment
- Conditions
- Type 2 Diabetes MellitusRenal Impairment
- Interventions
- Drug: LX4211 Placebo
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2013-09-09
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT01555008
- Locations
- 🇺🇸
Lexicon Investigational Site, Renton, Washington, United States
Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
- Conditions
- Primary Open-angle GlaucomaOcular Hypertension
- Interventions
- Drug: LX7101 VehicleDrug: LX7101 (0.125%)Drug: LX7101 (0.25%)
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2015-09-14
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT01528111
- Locations
- 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Drug: 250 mg LX1033 tabletsDrug: Placebo tablet
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 373
- Registration Number
- NCT01494233
- Locations
- 🇺🇸
Lexicon Investigational Site, Virginia Beach, Virginia, United States
A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT01456052
- Locations
- 🇸🇰
Lexicon Investigational Site, Nove Mesto nad Vahom, Slovakia
A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT01441232
- Locations
- 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States
A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: 50 mg LX3305 QDDrug: 100 mg LX3305 QDDrug: 150 mg LX3305 QDDrug: 200 mg LX3305 QDDrug: 250 mg LX3305 QDDrug: 300 mg LX3305 QDDrug: 400 mg LX3305 QDDrug: 250 mg LX3305 BIDDrug: 500 mg LX3305 QDDrug: Placebo
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT01417052
- Locations
- 🇺🇸
Lexicon Investigational Site, Dallas, Texas, United States
An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Drug: 250 mg capsuleDrug: 250 mg tablets
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2012-07-20
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT01411800
- Locations
- 🇺🇸
Lexicon Investigational Site, Overland Park, Kansas, United States